Leukemia  >>  Phase 1
Welcome,         Profile    Billing    Logout  

406 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leukemia
NCT04806035: Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Active, not recruiting
1
60
US
TG-1801, NI-1701, Ublituximab, TG-1101, LFB-R603
TG Therapeutics, Inc.
CLL, SLL, Richter's Transformation, Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Aggressive Lymphoma, DLBCL, Mediastinal Large B-cell Lymphoma, MCL
12/24
12/24
NX-2127-001, NCT04830137: A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Active, not recruiting
1
160
US
NX-2127
Nurix Therapeutics, Inc.
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), Primary Central Nervous System Lymphoma (PCNSL)
12/24
12/25
NCT04953910: Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

Recruiting
1
27
Europe
ASTX727, Oral decitabine and cedazuridine
Astex Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
12/24
12/24
NCT05558124: CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

Recruiting
1
18
US
Vyxeos, daunorubicin-cytarabine, CPX-351, Gemtuzumab Ozogamicin, Mylotarg
H. Lee Moffitt Cancer Center and Research Institute, Jazz Pharmaceuticals
Acute Myeloid Leukemia
11/25
11/25
NCT03400176: VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Terminated
1
39
US
VAY736, ibrutinib, Imbruvica
Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia (CLL)
09/23
09/23
NCT04953897: Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

Recruiting
1
18
Europe
ASTX727, Oral decitabine and cedazuridine
Astex Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
12/24
12/24
NCT05367700: A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

Recruiting
1
108
RoW
HS-10382(Part 1: Dose escalation), HS-10382(Part 2: Dose expansion)
Jiangsu Hansoh Pharmaceutical Co., Ltd.
CML, Chronic Phase, CML, Accelerated Phase
12/24
09/26
NCT03974217: Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Recruiting
1
12
US
Talazoparib, Talzenna, Decitabine, Dacogen
Dana-Farber Cancer Institute, Pfizer
Leukemia
12/24
06/25
NCT04227847: A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

Recruiting
1
140
Europe, US
SEA-CD70, azacitidine, VIDAZA
Seagen Inc.
Myelodysplastic Syndrome, Acute Myeloid Leukemia
12/24
11/26
RG1121403, NCT04797767: Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Suspended
1
20
US
Cladribine, 2-CdA, 2CDA, CdA, Cladribina, Leustat, Leustatin, Leustatine, RWJ-26251, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Mitoxantrone, Dihydroxyanthracenedione, Mitozantrone, Recombinant Granulocyte Colony-Stimulating Factor, Recombinant Colony-Stimulating Factor 3, rhG-CSF, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
University of Washington, AbbVie
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myeloid Neoplasm, Relapsed Acute Biphenotypic Leukemia, Relapsed Acute Myeloid Leukemia, Relapsed Mixed Phenotype Acute Leukemia, Relapsed Myeloid Neoplasm, Refractory Acute Biphenotypic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myeloid Neoplasm, Recurrent Myeloid Sarcoma
12/24
12/24
NCT05455294: Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Recruiting
1
36
US
Navitoclax, ABT-263, Venetoclax, Venclexta, Decitabine, Dacogen
Jacqueline Garcia, MD, AbbVie
Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis, Acute Myeloid Leukemia, Myeloproliferative Neoplasm
12/24
12/26
NCT05641259: A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

Recruiting
1
198
RoW
LP-108, Azacitidine
Guangzhou Lupeng Pharmaceutical Company LTD.
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
12/24
12/25
NCT04139434: Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

Active, not recruiting
1
36
Europe, US
LP-108, LP-108 and azacitidine
Newave Pharmaceutical Inc
AML/MDS, CMML, Relapse, Refractory Acute Lymphoblastic Leukemia, Relapse Leukemia, Relapsed Adult AML
01/25
01/25
ACHIEVE2, NCT06463327: - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML

Not yet recruiting
1
69
NA
TCB008, CD3+ T cells expressing the γ-chain variable region 9 δ-chain variable region 2 (Vγ9Vδ2) T cell receptor (TCR)
TC Biopharm
Acute Myeloid Leukemia, Myelodysplastic Syndromes
06/26
06/27
NCT05576181: Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia

Not yet recruiting
1
19
NA
ThisCART19A, Fludarabine Oral Tablet, Cyclophosphamide, VP-16, etoposide, HSCT
Fundamenta Therapeutics, Ltd., The First Affiliated Hospital of Zhengzhou University
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
01/25
07/25
NCT02735083 / 2016-000297-38: A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19

Active, not recruiting
1
28
Europe, Japan, US
UCART19 follow-up
Institut de Recherches Internationales Servier, ADIR, a Servier Group company
Advanced Lymphoid Leukemia
02/25
02/25
NCT04789655: Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1
80
Europe, Canada, US
CC-96191
Celgene
Leukemia, Myeloid
02/25
02/25
NCT05225584: Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Recruiting
1
120
US
KT-333
Kymera Therapeutics, Inc.
Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), T-cell Prolymphocytic Leukemia (T-PLL), Solid Tumors
02/25
03/25
NCT05094206: CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

Active, not recruiting
1
48
US
0.75x10^6 cells/kg CAR20.19.22 cells, 1x10^6 cells/kg CAR20.19.22 cells, 2.5x10^6 cells/kg CAR20.19.22 cells, 5x10^6 cells/kg CAR20.19.22 cells, Dose expansion: The maximum tolerated dose of CAR20.19.22 cells
Medical College of Wisconsin, Miltenyi Biomedicine GmbH
B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia
02/25
02/26
NCT05829226: A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Recruiting
1
90
US
LYT-200, Venetoclax, Azacitidine, Decitabine
PureTech
AML, Adult Recurrent, MDS
02/25
05/25
NCT05654779: CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated
1
4
RoW
LCAR-AMDR Cells Product
Institute of Hematology & Blood Diseases Hospital, China, Nanjing Legend Biotech Co.
Acute Myeloid Leukemia
09/23
09/23
NCT05748197: A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia

Recruiting
1
40
US
ADCLEC.syn1 CAR T cells, Conditioning chemotherapy
Memorial Sloan Kettering Cancer Center, Takeda
Acute Myeloid Leukemia
04/28
04/28
NCT05397496: Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

Recruiting
1
140
Europe, Japan, US, RoW
PIT565
Novartis Pharmaceuticals
B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)
06/27
06/28
NCT03085173: A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

Active, not recruiting
1
39
US
EGFRt/19-28z/4-1BBL CAR T cells
Memorial Sloan Kettering Cancer Center, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Chronic Lymphocytic Leukemia (CLL), Relapsed, Refractory
03/25
03/25
CP-MGD024-01, NCT05362773: A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Recruiting
1
90
US
MGD024
MacroGenics
Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell, Leukemia, Hairy Cell, Mastocytosis, Aggressive Systemic, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia
03/25
03/25
NCT05817058: First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
50
Europe
AFM28
Affimed GmbH
Acute Myeloid Leukemia
03/25
03/26
SGR-1505-101, NCT05544019: Study of SGR-1505 in Mature B-Cell Neoplasms

Recruiting
1
52
US, RoW
SGR-1505
Schrödinger, Inc.
Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
03/26
03/26
NCT05986240: Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

Recruiting
1
24
US
Danvatirsen, AZD9150, Danvatirsen + Venetoclax, Venclexta
Montefiore Medical Center, M.D. Anderson Cancer Center, Flamingo Therapeutics NV
AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes
10/25
07/28
PRT2527-02, NCT05665530: A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies

Recruiting
1
104
Europe, Canada, US, RoW
PRT2527, Zanubrutinib
Prelude Therapeutics, BeiGene
Aggressive B-Cell Non-Hodgkin's Lymphoma, Aggressive B-Cell NHL, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma
04/25
04/25
NCT05292664: Venetoclax Basket Trial for High Risk Hematologic Malignancies

Recruiting
1
92
US
Venetoclax, Venclexta, Azacitidine, Vidaza, Cytarabine, Ara-C, Arabinosylcytosine, Methotrexate, Amethopterin, Methotrexate Sodium, MTX, Hydrocortisone, Cortisone, Hydrocortisone Sodium Succinate, Hydrocortisone Sodium Phosphate, Leucovorin, Calcium Leucovorin,, Citrovorum Factor, Folinic Acid, Dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate, Vincristine, Vincristine Sulfate, LCR, VCR, Doxorubicin, Adriamycin, Rubex, Dexrazoxane, Zinecard, Calaspargase Pegol, Asparlas, Erwinia asparaginase, Rylze or native Erwinia asparaginase
Andrew E. Place, MD, AbbVie, Servier, Children's Cancer Research Fund, University of Colorado, Denver, Boston Children's Hospital, Gateway for Cancer Research
Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Lymphoblastic Lymphoma, in Relapse, Lymphoblastic Lymphoma, Refractory, Acute Leukemia of Ambiguous Lineage in Relapse, Acute Leukemia of Ambiguous Lineage
04/25
04/27
NCT04210219: A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Active, not recruiting
1
85
Europe, US, RoW
JNJ-64264681
Janssen Research & Development, LLC
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
04/26
04/26
NCT04230265: Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies

Recruiting
1
90
Europe
Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), TM123 (IMP), UniCAR02-T (IMP)
AvenCell Europe GmbH, PHARMALOG Institut für klinische Forschung GmbH
Acute Myeloid Leukemia (AML)
05/25
09/25
NCT05107856: PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Terminated
1
21
US
PRT1419, Azacitidine, Venetoclax
Prelude Therapeutics
Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma
01/24
01/24
NCT05787496: A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

Recruiting
1
63
US
NC525
NextCure, Inc.
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome
05/25
05/25
NCT06008405: Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy

Recruiting
1
48
RoW
TQB2928 Injection + Azacitidine for injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
05/25
05/25
NCT05155709 / 2021-001165-21: A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

Active, not recruiting
1
14
Europe, US, RoW
siremadlin, HDM201, venetoclax, azacitidine
Novartis Pharmaceuticals, Novartis Pharma AG
Acute Myeloid Leukemia
05/24
05/24
NCT06034275: Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Jul 2022 - Dec 2023: Topline data from trial solid tumors
Recruiting
1
36
US
VIP943
Vincerx Pharma, Inc.
Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
05/25
12/25
NCT05044039: Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

Recruiting
1
43
US
Duvelisib
Washington University School of Medicine, SecuraBio, The Foundation for Barnes-Jewish Hospital, National Cancer Institute (NCI)
Non-hodgkin Lymphoma, Acute Lymphocytic Leukemia
12/25
05/30
NCT02494882: Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older

Active, not recruiting
1
12
US
Ruxolitinib, Dasatinib, Dexamethasone
Memorial Sloan Kettering Cancer Center, Incyte Corporation, Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia
06/25
06/25
NCT05949125: Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123

Recruiting
1
37
Europe
Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), R-TM123, R-TM123 is one component of the Allo-RevCAR01-T-CD123 treatment, Allo-RevCAR01-T, Allo-RevCAR01-T is one component of the Allo-RevCAR01-T-CD123 treatment
AvenCell Europe GmbH, Allucent (NL) BV
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
12/25
06/26
NCI-2021-01791, NCT04872790: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Recruiting
1
20
US
Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Blinatumomab, 853426-35-4, AMG 103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI-538, MEDI538, MT103, Bone Marrow Aspiration and Biopsy, Lumbar Puncture, LP, spinal tap, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection
OHSU Knight Cancer Institute, AbbVie, Oregon Health and Science University
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
06/25
06/26
NCT05445011: Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia

Recruiting
1
12
RoW
Fludarabine + Cyclophosphamide + TAA05 Cell Injection, Fludarabine + Cyclophosphamide + Anti-FLT3 CAR-T Cell
Wuhan Union Hospital, China, PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Acute Myeloid Leukemia
06/25
06/27
CARxALL, NCT05679895: Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL

Recruiting
1
12
Europe
CD1a-CAR T
OneChain Immunotherapeutics, BioClever 2005 S.L., Hospital Clinic of Barcelona, Hospital Sant Joan de Deu
T-cell Acute Lymphoblastic Leukemia, Lymphoblastic T-Cell Lymphoma
06/25
01/26
POLARIS2020-002, NCT05001828: Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Recruiting
1
60
US
ADI-PEG 20, Venetoclax, Azacitidine
Polaris Group
Acute Myeloid Leukemia, Adult
07/25
12/25
NCT05947344: A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)

Recruiting
1
84
RoW
STI-8591, STI-8591 alone
Zhejiang ACEA Pharmaceutical Co. Ltd.
AML, Adult
07/25
07/25
COVALENT-103, NCT05918692: A Phase 1, Study of BMF-500 in Adults With Acute Leukemia

Recruiting
1
110
US
BMF-500
Biomea Fusion Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia
07/25
07/26
NCT05143996: CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Recruiting
1
60
US
CLN-049
Cullinan Oncology Inc.
Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
08/25
11/25
NCT05924750: A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
26
RoW
BL-M11D1
Sichuan Baili Pharmaceutical Co., Ltd.
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
08/25
08/25
NCT05534620: Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

Recruiting
1
36
US
Treosulfan, Fludarabine
medac GmbH, Synteract, Inc.
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
08/25
12/25
MK-0482-002, NCT05038800: A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Terminated
1
12
Europe, US, RoW
MK-0482
Merck Sharp & Dohme LLC
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia
12/23
12/23
FHD-286-C-002, NCT04891757: FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Recruiting
1
144
US
FHD-286, Low Dose Cytarabine, LDAC, Decitabine
Foghorn Therapeutics Inc.
Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes, Relapsed Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia
09/25
06/27
NCT05316116: Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

Recruiting
1
20
US
Siltuximab, Interleukin-6
H. Lee Moffitt Cancer Center and Research Institute, EUSA Pharma, Inc.
Large Granular Lymphocyte Leukemia
01/25
01/25
NCT04808115: IIT PH1 KDS-1001 in Patients With CML

Not yet recruiting
1
12
NA
KDS-1001
Lindsay Rein, MD, Kiadis Pharma
CML (Chronic Myelogenous Leukemia
09/25
09/27
Pediatric AML, NCT05622591: ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML

Withdrawn
1
21
NA
ELU001
Elucida Oncology, Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL)
Acute Myeloid Leukemia, AML, Childhood, Relapsed Pediatric AML, Refractory Pediatric AML
09/25
04/26
BHARAT-1, NCT05607199: A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics

Recruiting
1
80
RoW
AUR103, AUR 103 Calcium
Aurigene Discovery Technologies Limited
Solid Tumor, Adult, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non Hodgkin Lymphoma
09/25
10/26
NCT05457010: Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

Recruiting
1
24
US
SPRX002, ARC-T Cells
Arcellx, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
09/25
11/25
NCT06045091: To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

Recruiting
1
18
RoW
Human BCMA targeted CAR-NK cells injection, BCMA CAR-NK
Hrain Biotechnology Co., Ltd., Shanghai Changzheng Hospital
Multiple Myeloma, Plasma Cell Leukemia
09/25
09/27
NCT05065866: Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Active, not recruiting
1
14
US
BMS-986345, Oral Azacitidine, Duvelisib, Copiktra
H. Lee Moffitt Cancer Center and Research Institute, Secura Bio, Inc.
Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma, Lymphocytic Leukemia
03/24
03/25
NCT04690595: BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

Recruiting
1
24
US
BAFFR-CAR T cells
PeproMene Bio, Inc., City of Hope Medical Center
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
11/26
11/27
NCT05679687: ThisCART19A Bridging to alloHSCT for R/R B-ALL

Recruiting
1
20
RoW
Treatment
The First Affiliated Hospital of Soochow University, Fundamenta Therapeutics, Ltd.
CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL
11/25
11/25
NCT04282668: A Study of TAS1440 With ATRA in Subjects With r/r AML

Active, not recruiting
1
80
US
TAS1440, TAS1440 + ATRA, Tretinoin, Vesanoid
Astex Pharmaceuticals, Inc.
Acute Myeloid Leukemia
12/25
12/25
NCT03829540: CD4CAR for CD4+ Leukemia and Lymphoma

Recruiting
1
20
US
CD4CAR
Huda Salman, iCell Gene Therapeutics
T-cell Lymphoma, T-cell Leukemia
12/25
12/37
NX-5948-301, NCT05131022: A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Recruiting
1
292
Europe, US
NX-5948
Nurix Therapeutics, Inc.
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL)
12/25
01/27
NCT05424380: A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS

Active, not recruiting
1
18
Europe, Canada
GSK3745417
GlaxoSmithKline
Leukemia, Myeloid, Acute
03/24
03/24
NCT05506956: Post-transplant Flotetuzumab for AML

Recruiting
1
16
US
Flotetuzumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, MacroGenics, National Cancer Institute (NCI)
Leukemia, Myeloid, Acute
12/25
12/27
SGR-2921-101, NCT05961839: Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Recruiting
1
50
US
SGR-2921
Schrödinger, Inc.
Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes
12/25
12/25
ELM-1, NCT02290951: Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

Checkmark Presentation of ELM-1 and ELM-2 data from trial for DLBCL at ASH 2022
Dec 2022 - Dec 2022: Presentation of ELM-1 and ELM-2 data from trial for DLBCL at ASH 2022
Checkmark Data from trial for DLBCL/FL at ASH 2020
Dec 2020 - Dec 2020: Data from trial for DLBCL/FL at ASH 2020
Active, not recruiting
1
200
Europe, US, RoW
Odronextamab multiple dose levels, REGN1979
Regeneron Pharmaceuticals
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
12/25
12/25
NCT05209152: AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

Completed
1
7
US
AMG 176, Azacitidine
Amgen
Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
12/23
12/23
APG-115-AC101, NCT04275518: A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Recruiting
1
102
RoW
APG-115, Azacitidine, Cytarabine
Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
12/25
12/25
NCT05513612: Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Withdrawn
1
20
RoW
Autologous CAR-T cells, Fludarabine, Fludara, Cyclophosphamide, Cytoxan
Shanghai Pudong Hospital, UTC Therapeutics Inc.
Acute Myeloid Leukemia (AML), B-cell Non-Hodgkin's Lymphoma (B-NHL), Multiple Myeloma (MM), T-Cell Leukemia/Lymphoma, Adult, B-cell Acute Lymphoblastic Leukemia (B-ALL)
12/25
12/26
NCT05694364: Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Recruiting
1
88
US
Fludarabine, Fludara, Cyclophosphamide, PRGN-3007
H. Lee Moffitt Cancer Center and Research Institute, Precigen, Inc
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Triple Negative Breast Cancer Malignancies
01/26
01/26
NCT05943496: Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Recruiting
1
25
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Echocardiography, EC, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Questionnaire Administration, Tafasitamab, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574
OHSU Knight Cancer Institute, Oregon Health and Science University, Incyte Corporation
Chronic Lymphocytic Leukemia
01/26
01/27
VNC-152-102, NCT04978779: A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Terminated
1
6
Europe, US
VIP152, BTKi
Vincerx Pharma, Inc.
Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Richter Syndrome, MYC Amplification, MYC Overexpression, MYC Translocation
05/23
05/23
NCT04914845: KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia

Recruiting
1
40
US
KPT-9274
University of Colorado, Denver, Karyopharm Therapeutics Inc
Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
02/26
02/27
NCT05512390: A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Recruiting
1
114
Canada, US, RoW
ABBV-319
AbbVie
Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma
02/27
02/27
NCT05091424: A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Recruiting
1
137
Europe, US, RoW
Mosunetuzumab, Lunsumio, Tocilizumab, Venetoclax, Venclyxto, Venclexta
Hoffmann-La Roche
Chronic Lymphocytic Leukemia
05/27
10/29
WP42004, NCT04580121: A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

Completed
1
59
Europe, Canada, US, RoW
RO7283420, Tocilizumab, Actemra, RoActemra, Dasatinib, Dexamethasone, Paracetamol/acetaminophen, Diphenhydramine
Hoffmann-La Roche
Acute Myeloid Leukemia
08/23
08/23
NCT05828589: A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Recruiting
1
85
RoW
BGB-21447
BeiGene
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Relapsed Follicular Lymphoma, Relapsed Marginal Zone Lymphoma, Relapse Diffuse Large B Cell Lymphoma, Relapsed Small Lymphocytic Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Richter Transformation, Refractory Diffuse Large B-cell Lymphoma, Transformed Non-Hodgkin Lymphoma
03/26
10/26
NCT03219450: A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

Recruiting
1
15
US
NeoVax, Neoantigen vaccine, Cyclophosphamide, Cytoxan, Pembrolizumab, Keytruda
Dana-Farber Cancer Institute, Oncovir, Inc., BioNTech SE, Merck Sharp & Dohme LLC
Lymphocytic Leukemia
03/26
03/28
NCT05377827: Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

Recruiting
1
54
US
WU-CART-007
Washington University School of Medicine, Wugen, Inc.
T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma, Adult T Cell Leukemia, Adult T Cell Lymphoma, T Cell Prolymphocytic Leukemia, Extranodal NK/T-cell Lymphoma, Transformed Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma
04/26
04/26
KOMET-007, NCT05735184: A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML

Recruiting
1
212
US
Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine
Kura Oncology, Inc.
Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma
05/26
05/27
NCT04951778: Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

Recruiting
1
120
Europe, Canada, US, RoW
CC-91633, BMS-986397
Celgene
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
05/26
05/27
NCT05168202: A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Active, not recruiting
1
218
Europe, Canada, US, RoW
CC-95251, BMS-986351, Azacitidine, Venetoclax
Bristol-Myers Squibb
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
06/26
06/26
NCT04464200: 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

Active, not recruiting
1
30
US
19(T2)28z1xx CAR T cells
Memorial Sloan Kettering Cancer Center, Takeda
Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Burkitt's Lymphoma, Primary CNS Lymphoma
07/26
07/26
NCT06049667: A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

Recruiting
1
72
RoW
NTQ2494 tablet
Nanjing Chia-tai Tianqing Pharmaceutical
Relapsed/Refractory Acute Myeloid Leukemia (AML)
08/26
08/26
NCT06110208: Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML

Recruiting
1
18
RoW
CLL1 and CD38 dual-target CAR-T injection
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Gracell Biotechnology Shanghai Co., Ltd.
Acute Myeloid Leukemia
08/26
10/26
NCT06001788: Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
171
US
Ziftomenib, KO-539, Fludarabine, Idarubicin, Cytarabine, Gilteritinib, Xospata, Granulocyte colony-stimulating factor
Kura Oncology, Inc.
AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
08/26
08/27
NCT05521087 / 2022-000380-46: A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

Not yet recruiting
1
80
US
JNJ-75276617, Fludarabine, Cytarabine, Intrathecal Chemotherapy, Dexamethasone, Vincristine, Pegaspargase
Janssen Research & Development, LLC, Janssen Research & Development, LLC
Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia of Ambiguous Lineage
09/26
01/30
IGM-8444-001, NCT04553692: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

Recruiting
1
430
Europe, US, RoW
Aplitabart (IGM-8444), FOLFIRI, Fluorouracil or 5-FU, Leucovorin, Irinotecan, Bevacizumab (and approved biosimilars), Avastin, Birinapant, Venetoclax, Venclexta, Gemcitabine, Gemzar, Docetaxel, Taxotere, Docefrez, Azacitidine, VIDAZA
IGM Biosciences, Inc.
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
06/26
08/27
ELVN-001-101, NCT05304377: A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

Recruiting
1
180
Europe, Canada, US, RoW
ELVN-001
Enliven Therapeutics
Chronic Myeloid Leukemia
12/26
12/26
ARDENT, NCT05878184: Study Evaluating SC291 in Subjects With r/r B-cell Malignancies

Recruiting
1
57
US, RoW
SC291, Cyclophosphamide, Fludarabine
Sana Biotechnology
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
12/26
12/27
NCT05971251: Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

Recruiting
1
24
US
Loncastuximab Tesirine and Acalabrutinib
Mayur Narkhede, ADC Therapeutics S.A.
Chronic Lymphocytic Leukemia
12/26
12/28
NCI-2023-03572, NCT06034470: Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Recruiting
1
30
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Echocardiography, EC, Fludarabine, Fluradosa, Granulocyte Colony-Stimulating Factor, Colony Stimulating Factor 3, Colony-Stimulating Factor (Granulocyte), Colony-Stimulating Factor 3, CSF3, G CSF, G-CSF, Granulocyte Colony Stimulating Factor, Pluripoietin, Idarubicin, 4-Demethoxydaunomycin, 4-Demethoxydaunorubicin, 4-DMDR, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Pivekimab Sunirine, Anti-CD123 ADC IMGN632, Antibody-drug Conjugate IMGN632, CD123-targeted ADC IMGN632, IMGN 632, IMGN-632, IMGN632
Fred Hutchinson Cancer Center, ImmunoGen, Inc.
Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm
12/26
12/27
20-1319.cc, NCT05287568: CC-486 and Venetoclax for Acute Myeloid Leukemia

Recruiting
1
22
US
Venetoclax, ABT-199, Abbvie, CC-486
University of Colorado, Denver, Bristol-Myers Squibb
AML
03/27
03/29
NCT06088888: TGRX-678 US Phase I for Subjects With Refractory or Advanced Chronic Myelogenous Leukemia

Recruiting
1
90
US
TGRX-678
Shenzhen TargetRx, Inc., M.D. Anderson Cancer Center
Chronic Myelogenous Leukemia
03/27
06/27
NCT05330377: GM-CLAG in Relapsed/Refractory FLT3-mutated AML

Withdrawn
1
15
US
Gilteritinib 40 MG Oral Tablet, Xospata, Cladribine, Leustatin, Cytarabine, cytosine arabinoside (Ara-C), Filgrastim, GCSF, Filgrastim sndz, Mitoxantrone, Novantrone
Ayman H Qasrawi, Astellas Pharma Inc
Acute Myeloid Leukemia
05/27
05/32
NCT05618028: Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Recruiting
1
100
Europe, US, RoW
ABBV-525
AbbVie
Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
06/27
06/27
NCT05581030: CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Recruiting
1
20
US
Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase Pegol, Asparlas, CalPeg, Rituximab, Rituxan
H. Lee Moffitt Cancer Center and Research Institute, Servier
Acute Lymphoblastic Leukemia
05/25
05/27
C1763102, NCT05602363: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Recruiting
1
110
US
AS-1763
Carna Biosciences, Inc.
B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
09/27
09/27
NCT05515406: A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

Recruiting
1
54
US
ONO-7018
Ono Pharmaceutical Co. Ltd
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
12/27
12/27
 

Download Options